J&J May Not Meet US COVID-19 Vaccine Supply Target For Spring: NYT By Reuters

(Reuters) – Johnson & Johnson (NYSE 🙂 is facing unexpected delays in manufacturing its coronavirus vaccine and may not be able to deliver the doses it promised the federal government for the spring, the New York Times reported Wednesday. US federal officials have been told that J&J is up to two months behind the original production schedule and will not catch up until the end of April, when it was supposed to have delivered more than 60 million doses. the NYT reported, citing people familiar with the situation. (https://nyti.ms/38EX4n9) The company and the U.S. Department of Health and Human Services did not immediately respond to Reuters requests for comment. Earlier this week, the J&J CEO said the company was on track to have close to 1 billion doses of COVID-19 vaccine by the end of 2021.

Disclaimer: Fusion Media wishes to remind you that the data contained on this website is not necessarily accurate or in real time. All CFDs (stocks, indices, futures) and Forex prices are not provided by exchanges but by market makers, so the prices may not be accurate and may differ from the actual market price, which means that prices are indicative and not appropriate for commercial purposes. Therefore, Fusion Media assumes no responsibility for any business losses you may incur as a result of the use of this data. Fusion Media or anyone involved with Fusion Media will not accept any responsibility for loss or damage as a result of reliance on information, including data, quotes, charts, and buy / sell signals contained on this website. Be fully informed about the risks and costs associated with trading the financial markets, it is one of the riskiest forms of investment possible.